Lexaria Bioscience: Ingesting Versus Inhaling Could Save 60,000 Lives a Year

“Everybody knows that smoking is not healthy. Thus, our technology delivers drug molecules like cannabinoids or nicotine through ingesting means. Also …

Lexaria Bioscience ingesting cannabinoids

Technology for healthier drug molecule delivery

“Everybody knows that smoking is not healthy. Thus, our technology delivers drug molecules like cannabinoids or nicotine through ingesting means. Also, the things that you swallow and that could be a pill, it could be a syrup, could be a cup of coffee. Therefore if we are able to help change the consumption habits of even 1 percent of the global marketplace who smoke we could save 60,000 lives a year.” – Chris Bunka, CEO of Lexaria Bioscience.

Lexaria Bioscience Corp. developed and out-licenses its technology named DehydraTECH™ that promotes -

  • Healthier administration methods
  • Lower overall dosing
  • Higher effectiveness of ingestible drugs and other beneficial molecules.

This technology is protected by a robust suite of patents granted or pending worldwide. Thus is proven effective in multiple international studies and quantity of absorption of a range of molecules. DehydraTECH delivery technology offers a workable and healthier alternative. Basically in other delivery methods for substances such as inhalational delivery through smoking.

For more information on Lexaria Bioscience Corp. (NASDAQ: LEXX) please fill out the form below.

No items found.

You might also like

Ivan Bebek on Where the Biggest Mining Returns May Still Lie
Metals & Mining
March 4, 2026

Ivan Bebek on Where the Biggest Mining Returns May Still Lie

Veteran mining entrepreneur Ivan Bebek believes the current gold and silver cycle may only be getting started.

This is some text inside of a div block.
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Health & Wellness
March 3, 2026

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

This is some text inside of a div block.
BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs
ETFs
March 3, 2026

BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs

In Canada, management fees for asset allocation ETFs can range from approximately 50 basis points down to 15 basis points.

This is some text inside of a div block.
Subscribe and receive the investor Info